Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 4 | 2017 | 160 | 1.060 |
Why?
|
| Palliative Care | 5 | 2020 | 52 | 1.040 |
Why?
|
| Sexual and Gender Minorities | 2 | 2017 | 31 | 1.040 |
Why?
|
| Goals | 1 | 2020 | 28 | 0.690 |
Why?
|
| Estrogens | 4 | 2013 | 60 | 0.610 |
Why?
|
| Bone Density | 6 | 2014 | 94 | 0.600 |
Why?
|
| Body Composition | 12 | 2016 | 91 | 0.570 |
Why?
|
| Organizational Objectives | 1 | 2017 | 14 | 0.550 |
Why?
|
| Aged | 22 | 2020 | 6129 | 0.540 |
Why?
|
| Program Development | 1 | 2017 | 64 | 0.530 |
Why?
|
| Community-Based Participatory Research | 1 | 2017 | 45 | 0.530 |
Why?
|
| Homosexuality | 1 | 2016 | 5 | 0.530 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2015 | 4 | 0.490 |
Why?
|
| Health Status Disparities | 1 | 2017 | 148 | 0.490 |
Why?
|
| Medication Therapy Management | 1 | 2015 | 5 | 0.480 |
Why?
|
| Obesity | 8 | 2016 | 814 | 0.450 |
Why?
|
| Homosexuality, Female | 1 | 2014 | 7 | 0.450 |
Why?
|
| Cultural Competency | 1 | 2014 | 12 | 0.450 |
Why?
|
| Bisexuality | 1 | 2014 | 11 | 0.440 |
Why?
|
| Social Work | 1 | 2014 | 15 | 0.440 |
Why?
|
| Homosexuality, Male | 1 | 2014 | 38 | 0.440 |
Why?
|
| Transgender Persons | 1 | 2014 | 33 | 0.430 |
Why?
|
| Humans | 38 | 2020 | 17376 | 0.430 |
Why?
|
| Female | 33 | 2019 | 12444 | 0.420 |
Why?
|
| Weight Loss | 5 | 2016 | 295 | 0.410 |
Why?
|
| Exercise | 7 | 2014 | 513 | 0.380 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 381 | 0.380 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2013 | 100 | 0.370 |
Why?
|
| Middle Aged | 24 | 2017 | 7885 | 0.360 |
Why?
|
| Postmenopause | 7 | 2014 | 248 | 0.350 |
Why?
|
| Male | 20 | 2019 | 9843 | 0.350 |
Why?
|
| Raloxifene Hydrochloride | 2 | 2013 | 12 | 0.340 |
Why?
|
| Saliva | 2 | 2005 | 11 | 0.300 |
Why?
|
| Muscle, Skeletal | 4 | 2012 | 35 | 0.300 |
Why?
|
| Social Workers | 2 | 2020 | 2 | 0.300 |
Why?
|
| Insulin | 7 | 2013 | 190 | 0.280 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 1942 | 0.270 |
Why?
|
| Adiposity | 3 | 2013 | 67 | 0.260 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2005 | 5 | 0.240 |
Why?
|
| Pituitary-Adrenal System | 1 | 2005 | 6 | 0.240 |
Why?
|
| Hydrocortisone | 1 | 2005 | 18 | 0.240 |
Why?
|
| Interviews as Topic | 2 | 2017 | 304 | 0.230 |
Why?
|
| Physical Endurance | 1 | 2003 | 4 | 0.210 |
Why?
|
| Hypogonadism | 1 | 2003 | 5 | 0.210 |
Why?
|
| Bone and Bones | 2 | 2014 | 10 | 0.210 |
Why?
|
| Dehydroepiandrosterone Sulfate | 3 | 2013 | 6 | 0.200 |
Why?
|
| Colorado | 4 | 2019 | 164 | 0.200 |
Why?
|
| Blood Glucose | 5 | 2013 | 315 | 0.190 |
Why?
|
| Adult | 12 | 2016 | 7529 | 0.180 |
Why?
|
| Lipid Metabolism | 2 | 2012 | 13 | 0.180 |
Why?
|
| Insulin Resistance | 2 | 2013 | 128 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2020 | 108 | 0.170 |
Why?
|
| Lipolysis | 2 | 2013 | 3 | 0.170 |
Why?
|
| Needs Assessment | 2 | 2014 | 68 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 47 | 0.160 |
Why?
|
| Caregivers | 1 | 2020 | 130 | 0.160 |
Why?
|
| Dehydroepiandrosterone | 2 | 2011 | 7 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 66 | 0.160 |
Why?
|
| Subcutaneous Fat | 2 | 2010 | 3 | 0.150 |
Why?
|
| Glycerol | 4 | 2013 | 5 | 0.150 |
Why?
|
| Culturally Competent Care | 1 | 2018 | 11 | 0.150 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2011 | 10 | 0.150 |
Why?
|
| Social Support | 2 | 2018 | 208 | 0.150 |
Why?
|
| Patient Navigation | 1 | 2018 | 19 | 0.150 |
Why?
|
| Advance Care Planning | 1 | 2018 | 21 | 0.150 |
Why?
|
| Patient Admission | 3 | 2015 | 69 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2019 | 405 | 0.130 |
Why?
|
| Ageism | 1 | 2016 | 2 | 0.130 |
Why?
|
| Caloric Restriction | 1 | 2016 | 4 | 0.130 |
Why?
|
| Energy Metabolism | 3 | 2013 | 48 | 0.130 |
Why?
|
| Independent Living | 1 | 2016 | 24 | 0.130 |
Why?
|
| Fasting | 1 | 2016 | 46 | 0.130 |
Why?
|
| Hispanic Americans | 1 | 2018 | 378 | 0.130 |
Why?
|
| Housing | 1 | 2016 | 37 | 0.130 |
Why?
|
| Focus Groups | 1 | 2016 | 144 | 0.130 |
Why?
|
| Health Personnel | 1 | 2017 | 126 | 0.120 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 7 | 0.120 |
Why?
|
| Qualitative Research | 1 | 2016 | 262 | 0.120 |
Why?
|
| Body Weight | 3 | 2016 | 203 | 0.120 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 88 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2016 | 253 | 0.110 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2013 | 11 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 2014 | 72 | 0.110 |
Why?
|
| Glucose | 2 | 2011 | 31 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 134 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2013 | 30 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 395 | 0.100 |
Why?
|
| Acetaminophen | 1 | 2012 | 4 | 0.100 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 4 | 0.100 |
Why?
|
| Resistance Training | 1 | 2012 | 5 | 0.100 |
Why?
|
| Thigh | 2 | 2010 | 11 | 0.100 |
Why?
|
| Cognition | 1 | 2013 | 81 | 0.100 |
Why?
|
| Receptors, CCR5 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cervix Uteri | 1 | 2012 | 5 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 14 | 0.100 |
Why?
|
| Thinness | 1 | 2012 | 31 | 0.090 |
Why?
|
| HIV-1 | 1 | 2012 | 71 | 0.090 |
Why?
|
| Absorptiometry, Photon | 4 | 2014 | 51 | 0.090 |
Why?
|
| Dietary Fats | 1 | 2012 | 89 | 0.090 |
Why?
|
| Hormone Replacement Therapy | 2 | 2008 | 20 | 0.090 |
Why?
|
| Hormone Antagonists | 1 | 2011 | 1 | 0.090 |
Why?
|
| Sympathetic Nervous System | 1 | 2011 | 3 | 0.090 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2011 | 42 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 439 | 0.090 |
Why?
|
| Intra-Abdominal Fat | 1 | 2010 | 14 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2015 | 2428 | 0.080 |
Why?
|
| Weight Gain | 1 | 2011 | 156 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2010 | 56 | 0.080 |
Why?
|
| Biomarkers | 4 | 2012 | 306 | 0.080 |
Why?
|
| Neuropsychological Tests | 2 | 2013 | 43 | 0.080 |
Why?
|
| Muscle Strength | 1 | 2008 | 12 | 0.070 |
Why?
|
| Motor Activity | 1 | 2008 | 208 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2006 | 34 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2006 | 60 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 295 | 0.060 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2005 | 1 | 0.060 |
Why?
|
| Radioimmunoassay | 1 | 2005 | 4 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2005 | 12 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 22 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2005 | 12 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2005 | 23 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2013 | 33 | 0.060 |
Why?
|
| Exercise Test | 1 | 2005 | 45 | 0.060 |
Why?
|
| HIV Infections | 1 | 2012 | 712 | 0.060 |
Why?
|
| Menstrual Cycle | 1 | 2005 | 5 | 0.060 |
Why?
|
| Basal Metabolism | 1 | 2005 | 5 | 0.060 |
Why?
|
| Adipose Tissue | 1 | 2005 | 65 | 0.060 |
Why?
|
| Radioisotope Dilution Technique | 1 | 2004 | 1 | 0.060 |
Why?
|
| Deuterium | 1 | 2004 | 3 | 0.060 |
Why?
|
| Body Water | 1 | 2004 | 3 | 0.060 |
Why?
|
| Serum | 1 | 2004 | 5 | 0.060 |
Why?
|
| Urine | 1 | 2004 | 5 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 300 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2016 | 211 | 0.060 |
Why?
|
| Glucose Clamp Technique | 3 | 2013 | 16 | 0.060 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2004 | 12 | 0.060 |
Why?
|
| Hypoventilation | 1 | 2004 | 1 | 0.050 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2004 | 8 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2003 | 17 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 1287 | 0.050 |
Why?
|
| Length of Stay | 1 | 2004 | 171 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 50 | 0.050 |
Why?
|
| Terminal Care | 1 | 2003 | 46 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2003 | 48 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2012 | 6 | 0.050 |
Why?
|
| Lipids | 2 | 2013 | 69 | 0.050 |
Why?
|
| Collagen Type I | 2 | 2012 | 6 | 0.050 |
Why?
|
| Peptides | 2 | 2012 | 14 | 0.050 |
Why?
|
| Weight Reduction Programs | 2 | 2014 | 49 | 0.050 |
Why?
|
| Obesity, Morbid | 1 | 2004 | 121 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2016 | 1170 | 0.050 |
Why?
|
| Energy Intake | 2 | 2016 | 98 | 0.050 |
Why?
|
| Triglycerides | 2 | 2012 | 83 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 203 | 0.040 |
Why?
|
| Calorimetry | 2 | 2012 | 2 | 0.040 |
Why?
|
| Linear Models | 3 | 2008 | 210 | 0.040 |
Why?
|
| Fatty Acids | 2 | 2012 | 8 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2003 | 251 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 366 | 0.040 |
Why?
|
| Diet | 3 | 2009 | 356 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 533 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2011 | 937 | 0.040 |
Why?
|
| Placebos | 2 | 2011 | 19 | 0.040 |
Why?
|
| Hip | 2 | 2011 | 9 | 0.040 |
Why?
|
| Lumbar Vertebrae | 2 | 2011 | 19 | 0.040 |
Why?
|
| Glucose Tolerance Test | 2 | 2013 | 107 | 0.040 |
Why?
|
| Kinetics | 2 | 2012 | 12 | 0.040 |
Why?
|
| Heart Failure | 1 | 2003 | 404 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2008 | 142 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 316 | 0.030 |
Why?
|
| Streptococcus agalactiae | 1 | 1997 | 8 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2013 | 1287 | 0.030 |
Why?
|
| Streptococcal Infections | 1 | 1997 | 22 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 2016 | 22 | 0.030 |
Why?
|
| Physical Fitness | 2 | 2008 | 70 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2006 | 10 | 0.030 |
Why?
|
| Population Surveillance | 1 | 1997 | 254 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 1155 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2008 | 342 | 0.030 |
Why?
|
| Femur Neck | 1 | 2014 | 5 | 0.030 |
Why?
|
| Executive Function | 1 | 2013 | 23 | 0.030 |
Why?
|
| Mathematical Concepts | 1 | 2013 | 3 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2012 | 3 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 86 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2012 | 9 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 2012 | 2 | 0.020 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 47 | 0.020 |
Why?
|
| DNA | 1 | 2012 | 23 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 5 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 5 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 37 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2012 | 5 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 52 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 22 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2011 | 5 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2011 | 2 | 0.020 |
Why?
|
| Oxytocics | 1 | 2011 | 2 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 82 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 69 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2011 | 27 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 38 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 112 | 0.020 |
Why?
|
| Risk Factors | 2 | 2010 | 3255 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2009 | 10 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1100 | 0.020 |
Why?
|
| Physical Exertion | 1 | 2009 | 15 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 275 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 140 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 13 | 0.020 |
Why?
|
| Testosterone | 1 | 2008 | 23 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 884 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2008 | 21 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 178 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 607 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 280 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2006 | 1 | 0.020 |
Why?
|
| Microdialysis | 1 | 2006 | 1 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 47 | 0.020 |
Why?
|
| Time Factors | 1 | 2009 | 1044 | 0.020 |
Why?
|
| Femur | 1 | 2006 | 10 | 0.020 |
Why?
|
| Calcium, Dietary | 1 | 2006 | 28 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2006 | 66 | 0.020 |
Why?
|
| Vitamin D | 1 | 2006 | 72 | 0.020 |
Why?
|
| Buttocks | 1 | 2005 | 1 | 0.020 |
Why?
|
| Abdomen | 1 | 2005 | 20 | 0.010 |
Why?
|
| Follicular Phase | 1 | 2005 | 1 | 0.010 |
Why?
|
| Luteal Phase | 1 | 2005 | 1 | 0.010 |
Why?
|
| Premenopause | 1 | 2005 | 24 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 367 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 2473 | 0.010 |
Why?
|
| Rest | 1 | 2004 | 2 | 0.010 |
Why?
|
| C-Peptide | 1 | 2004 | 6 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 34 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2004 | 2 | 0.010 |
Why?
|
| Bicarbonates | 1 | 2004 | 3 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2004 | 21 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2004 | 17 | 0.010 |
Why?
|
| Attitude to Death | 1 | 2003 | 6 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 231 | 0.010 |
Why?
|
| Psychometrics | 1 | 2004 | 119 | 0.010 |
Why?
|
| Hyperinsulinism | 1 | 2003 | 8 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 203 | 0.010 |
Why?
|
| Estradiol | 1 | 2003 | 23 | 0.010 |
Why?
|
| Critical Care | 1 | 2004 | 67 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 145 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2003 | 93 | 0.010 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2004 | 216 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 564 | 0.010 |
Why?
|
| Physicians | 1 | 2003 | 128 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 702 | 0.010 |
Why?
|
| Mass Screening | 1 | 2006 | 671 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 2526 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2003 | 666 | 0.010 |
Why?
|
| Adolescent | 1 | 2004 | 3533 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1997 | 805 | 0.010 |
Why?
|
Concepts
(256)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(6)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->